Does the media favor SGHT or INSP?

In the previous week, Inspire Medical Systems had 3 more articles in the media than Sight Sciences. MarketBeat recorded 7 mentions for Inspire Medical Systems and 4 mentions for Sight Sciences. Inspire Medical Systems' average media sentiment score of 1.23 beat Sight Sciences' score of 0.26 indicating that Inspire Medical Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inspire Medical Systems 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, SGHT or OMCL?

Omnicell has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sight Sciences $77.36M 5.71 -$38.43M -$0.56 N/A Omnicell $1.18B 1.24 $2.05M $0.84 38.37

Is SGHT or OMCL more profitable?

Omnicell has a net margin of 3.13% compared to Sight Sciences' net margin of -35.69%. Omnicell's return on equity of 5.66% beat Sight Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Sight Sciences -35.69% -43.39% -22.86% Omnicell 3.13% 5.66% 3.57%

Does the media prefer SGHT or OMCL?

In the previous week, Sight Sciences had 2 more articles in the media than Omnicell. MarketBeat recorded 4 mentions for Sight Sciences and 2 mentions for Omnicell. Omnicell's average media sentiment score of 0.83 beat Sight Sciences' score of 0.26 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Omnicell 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KMTS or SGHT?

In the previous week, Kestra Medical Technologies had 15 more articles in the media than Sight Sciences. MarketBeat recorded 19 mentions for Kestra Medical Technologies and 4 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 0.26 beat Kestra Medical Technologies' score of -0.02 indicating that Sight Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kestra Medical Technologies 2 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Sight Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, CNMD or SGHT?

CONMED has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CONMED $1.37B 0.99 $47.06M $1.85 24.55 Sight Sciences $77.36M 5.71 -$38.43M -$0.56 N/A

Is CNMD or SGHT more profitable?

CONMED has a net margin of 4.12% compared to Sight Sciences' net margin of -35.69%. CONMED's return on equity of 14.31% beat Sight Sciences' return on equity. Company Net Margins Return on Equity Return on Assets CONMED 4.12% 14.31% 6.33% Sight Sciences -35.69% -43.39% -22.86%

Does the media favor CNMD or SGHT?

In the previous week, Sight Sciences had 3 more articles in the media than CONMED. MarketBeat recorded 4 mentions for Sight Sciences and 1 mentions for CONMED. CONMED's average media sentiment score of 0.45 beat Sight Sciences' score of 0.26 indicating that CONMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CONMED 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sight Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ATEC or SGHT more profitable?

Alphatec has a net margin of -13.49% compared to Sight Sciences' net margin of -35.69%. Sight Sciences' return on equity of -43.39% beat Alphatec's return on equity. Company Net Margins Return on Equity Return on Assets Alphatec -13.49% -6,752.24% -13.88% Sight Sciences -35.69% -43.39% -22.86%

Does the media refer more to ATEC or SGHT?

In the previous week, Alphatec and Alphatec both had 4 articles in the media. Alphatec's average media sentiment score of 0.75 beat Sight Sciences' score of 0.26 indicating that Alphatec is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alphatec 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sight Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sight Sciences (SGHT) Competitors

$8.02 -0.06 (-0.74%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$8.02 0.00 (0.00%)

As of 09/18/2026 04:11 PM Eastern

Compare

SGHT vs. INSP, OMCL, KMTS, CNMD, and ATEC

Should you buy Sight Sciences stock or one of its competitors? Sight Sciences's main competitors and comparable companies include Inspire Medical Systems (INSP), Omnicell (OMCL), Kestra Medical Technologies (KMTS), CONMED (CNMD), and Alphatec (ATEC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Sight Sciences compare to Inspire Medical Systems?

Sight Sciences (NASDAQ:SGHT) and Inspire Medical Systems (NYSE:INSP) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Sight Sciences currently has a consensus target price of $7.88, indicating a potential downside of 1.81%. Inspire Medical Systems has a consensus target price of $66.50, indicating a potential downside of 13.47%. Given Sight Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe Sight Sciences is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inspire Medical Systems	3 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.21

Inspire Medical Systems has a net margin of 15.03% compared to Sight Sciences' net margin of -35.69%. Inspire Medical Systems' return on equity of 8.64% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-35.69%	-43.39%	-22.86%
Inspire Medical Systems	15.03%	8.64%	7.45%

55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are held by institutional investors. 30.4% of Sight Sciences shares are held by company insiders. Comparatively, 2.2% of Inspire Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Inspire Medical Systems has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	5.71	-$38.43M	-$0.56	N/A
Inspire Medical Systems	$911.98M	2.44	$145.42M	$4.62	16.63

In the previous week, Inspire Medical Systems had 3 more articles in the media than Sight Sciences. MarketBeat recorded 7 mentions for Inspire Medical Systems and 4 mentions for Sight Sciences. Inspire Medical Systems' average media sentiment score of 1.23 beat Sight Sciences' score of 0.26 indicating that Inspire Medical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sight Sciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inspire Medical Systems	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sight Sciences has a beta of 2.5, meaning that its share price is 150% more volatile than the broader market. Comparatively, Inspire Medical Systems has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Summary

Inspire Medical Systems beats Sight Sciences on 11 of the 17 factors compared between the two stocks.

How does Sight Sciences compare to Omnicell?

Sight Sciences (NASDAQ:SGHT) and Omnicell (NASDAQ:OMCL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 30.4% of Sight Sciences shares are held by company insiders. Comparatively, 2.9% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Omnicell has a net margin of 3.13% compared to Sight Sciences' net margin of -35.69%. Omnicell's return on equity of 5.66% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-35.69%	-43.39%	-22.86%
Omnicell	3.13%	5.66%	3.57%

Sight Sciences has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market. Comparatively, Omnicell has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

In the previous week, Sight Sciences had 2 more articles in the media than Omnicell. MarketBeat recorded 4 mentions for Sight Sciences and 2 mentions for Omnicell. Omnicell's average media sentiment score of 0.83 beat Sight Sciences' score of 0.26 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sight Sciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omnicell	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omnicell has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	5.71	-$38.43M	-$0.56	N/A
Omnicell	$1.18B	1.24	$2.05M	$0.84	38.37

Sight Sciences presently has a consensus price target of $7.88, suggesting a potential downside of 1.81%. Omnicell has a consensus price target of $57.86, suggesting a potential upside of 79.51%. Given Omnicell's stronger consensus rating and higher probable upside, analysts plainly believe Omnicell is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Omnicell beats Sight Sciences on 12 of the 16 factors compared between the two stocks.

How does Sight Sciences compare to Kestra Medical Technologies?

Kestra Medical Technologies (NASDAQ:KMTS) and Sight Sciences (NASDAQ:SGHT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

55.5% of Sight Sciences shares are owned by institutional investors. 5.3% of Kestra Medical Technologies shares are owned by company insiders. Comparatively, 30.4% of Sight Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sight Sciences has lower revenue, but higher earnings than Kestra Medical Technologies. Sight Sciences is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kestra Medical Technologies	$95.13M	15.30	-$131.61M	-$2.67	N/A
Sight Sciences	$77.36M	5.71	-$38.43M	-$0.56	N/A

Kestra Medical Technologies has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market.

Sight Sciences has a net margin of -35.69% compared to Kestra Medical Technologies' net margin of -140.43%. Sight Sciences' return on equity of -43.39% beat Kestra Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kestra Medical Technologies	-140.43%	-63.83%	-44.76%
Sight Sciences	-35.69%	-43.39%	-22.86%

Kestra Medical Technologies currently has a consensus price target of $28.38, indicating a potential upside of 16.15%. Sight Sciences has a consensus price target of $7.88, indicating a potential downside of 1.81%. Given Kestra Medical Technologies' higher probable upside, equities research analysts clearly believe Kestra Medical Technologies is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kestra Medical Technologies	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Kestra Medical Technologies had 15 more articles in the media than Sight Sciences. MarketBeat recorded 19 mentions for Kestra Medical Technologies and 4 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 0.26 beat Kestra Medical Technologies' score of -0.02 indicating that Sight Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kestra Medical Technologies	2 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sight Sciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sight Sciences beats Kestra Medical Technologies on 11 of the 16 factors compared between the two stocks.

How does Sight Sciences compare to CONMED?

CONMED (NYSE:CNMD) and Sight Sciences (NASDAQ:SGHT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

CONMED has a net margin of 4.12% compared to Sight Sciences' net margin of -35.69%. CONMED's return on equity of 14.31% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CONMED	4.12%	14.31%	6.33%
Sight Sciences	-35.69%	-43.39%	-22.86%

CONMED currently has a consensus target price of $41.40, indicating a potential downside of 8.85%. Sight Sciences has a consensus target price of $7.88, indicating a potential downside of 1.81%. Given Sight Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Sight Sciences is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CONMED	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Sight Sciences had 3 more articles in the media than CONMED. MarketBeat recorded 4 mentions for Sight Sciences and 1 mentions for CONMED. CONMED's average media sentiment score of 0.45 beat Sight Sciences' score of 0.26 indicating that CONMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CONMED	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sight Sciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CONMED has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.5, indicating that its stock price is 150% more volatile than the broader market.

55.5% of Sight Sciences shares are owned by institutional investors. 0.3% of CONMED shares are owned by insiders. Comparatively, 30.4% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CONMED has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CONMED	$1.37B	0.99	$47.06M	$1.85	24.55
Sight Sciences	$77.36M	5.71	-$38.43M	-$0.56	N/A

Summary

CONMED and Sight Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Sight Sciences compare to Alphatec?

Alphatec (NASDAQ:ATEC) and Sight Sciences (NASDAQ:SGHT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Sight Sciences has lower revenue, but higher earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alphatec	$764.16M	2.06	-$143.36M	-$0.71	N/A
Sight Sciences	$77.36M	5.71	-$38.43M	-$0.56	N/A

Alphatec currently has a consensus price target of $17.40, indicating a potential upside of 70.92%. Sight Sciences has a consensus price target of $7.88, indicating a potential downside of 1.81%. Given Alphatec's stronger consensus rating and higher probable upside, research analysts clearly believe Alphatec is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alphatec	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Alphatec has a net margin of -13.49% compared to Sight Sciences' net margin of -35.69%. Sight Sciences' return on equity of -43.39% beat Alphatec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alphatec	-13.49%	-6,752.24%	-13.88%
Sight Sciences	-35.69%	-43.39%	-22.86%

Alphatec has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market.

66.4% of Alphatec shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 13.5% of Alphatec shares are held by company insiders. Comparatively, 30.4% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Alphatec and Alphatec both had 4 articles in the media. Alphatec's average media sentiment score of 0.75 beat Sight Sciences' score of 0.26 indicating that Alphatec is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alphatec	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sight Sciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alphatec beats Sight Sciences on 8 of the 15 factors compared between the two stocks.

Get Sight Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGHT vs. The Competition

Export

Metric	Sight Sciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$441.81M	$5.55B	$7.24B	$13.19B
Dividend Yield	N/A	1.80%	2.57%	12.81%
P/E Ratio	-14.32	25.34	275.49	25.40
Price / Sales	5.71	72.49	646.01	89.45
Price / Cash	N/A	32.64	76.25	51.42
Price / Book	6.63	5.69	10.46	6.33
Net Income	-$38.43M	$151.55M	$3.49B	$358.33M
7 Day Performance	-1.47%	0.66%	0.59%	1.12%
1 Month Performance	-1.60%	-3.33%	-1.74%	-2.39%
1 Year Performance	122.78%	6.79%	18.13%	5.35%

Sight Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGHT Sight Sciences	1.3178 of 5 stars	$8.02 -0.7%	$7.88 -1.8%	+122.8%	$441.81M	$77.36M	N/A	186	News Coverage High Trading Volume
INSP Inspire Medical Systems	3.2626 of 5 stars	$62.30 -1.2%	$66.19 +6.2%	-3.8%	$1.82B	$911.98M	13.48	1,333	Positive News
OMCL Omnicell	4.1975 of 5 stars	$33.88 -1.4%	$57.86 +70.8%	+2.8%	$1.56B	$1.18B	40.33	3,580	Positive News
KMTS Kestra Medical Technologies	1.7109 of 5 stars	$25.64 +0.4%	$28.14 +9.8%	-2.0%	$1.50B	$95.13M	N/A	300	Earnings Report Analyst Forecast
CNMD CONMED	1.5064 of 5 stars	$46.61 -5.5%	$41.40 -11.2%	-9.2%	$1.48B	$1.37B	25.20	3,900	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGHT) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sight Sciences (SGHT) Competitors

SGHT vs. INSP, OMCL, KMTS, CNMD, and ATEC

How does Sight Sciences compare to Inspire Medical Systems?

Summary

How does Sight Sciences compare to Omnicell?

Summary

How does Sight Sciences compare to Kestra Medical Technologies?

Summary

How does Sight Sciences compare to CONMED?

Summary

How does Sight Sciences compare to Alphatec?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGHT vs. The Competition

Sight Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sight Sciences (SGHT) Competitors

SGHT vs. INSP, OMCL, KMTS, CNMD, and ATEC

How does Sight Sciences compare to Inspire Medical Systems?

Do analysts recommend SGHT or INSP?

Is SGHT or INSP more profitable?

Do insiders and institutionals have more ownership in SGHT or INSP?

Which has better earnings & valuation, SGHT or INSP?

Does the media favor SGHT or INSP?

Which has more volatility and risk, SGHT or INSP?

Summary

How does Sight Sciences compare to Omnicell?

Do institutionals and insiders hold more shares of SGHT or OMCL?

Is SGHT or OMCL more profitable?

Which has more risk & volatility, SGHT or OMCL?

Does the media prefer SGHT or OMCL?

Which has higher valuation & earnings, SGHT or OMCL?

Do analysts rate SGHT or OMCL?

Summary

How does Sight Sciences compare to Kestra Medical Technologies?

Do institutionals & insiders have more ownership in KMTS or SGHT?

Which has higher earnings and valuation, KMTS or SGHT?

Which has more volatility & risk, KMTS or SGHT?

Is KMTS or SGHT more profitable?

Do analysts rate KMTS or SGHT?

Does the media refer more to KMTS or SGHT?

Summary

How does Sight Sciences compare to CONMED?

Is CNMD or SGHT more profitable?

Do analysts rate CNMD or SGHT?

Does the media favor CNMD or SGHT?

Which has more volatility and risk, CNMD or SGHT?

Do institutionals and insiders believe in CNMD or SGHT?

Which has better earnings and valuation, CNMD or SGHT?

Summary

How does Sight Sciences compare to Alphatec?

Which has stronger earnings and valuation, ATEC or SGHT?

Do analysts recommend ATEC or SGHT?

Is ATEC or SGHT more profitable?

Which has more volatility and risk, ATEC or SGHT?

Do institutionals and insiders have more ownership in ATEC or SGHT?

Does the media refer more to ATEC or SGHT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGHT vs. The Competition

Sight Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools